Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models

Protein Binding Affinity of Polymeric Nanoparticles as a Direct Indicator of Their Pharmacokinetics

(2020) Zhi-Ting Cao et al.   ACS Nano

Polymersomes for Therapeutic Delivery of Protein and Nucleic Acid Macromolecules: From Design to Therapeutic Applications

(2020) Shoaib Iqbal et al.   BIOMACROMOLECULES

Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts

(2020) Linlin Shi et al.   JOURNAL OF CONTROLLED RELEASE

Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy

(2020) Ashutosh Barve et al.   Acta Biomaterialia

Facile Hydrophobization of siRNA with Anticancer Drug for Non-Cationic Nanocarrier-Mediated Systemic Delivery

(2019) Congfei Xu et al.   NANO LETTERS

AKT as a Therapeutic Target for Cancer

(2019) Mengqiu Song et al.   CANCER RESEARCH

Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression

(2019) Yi-Hui Wu et al.   Cell Death & Disease

Akt in cancer: Mediator and more

(2019) Sundaramoorthy Revathidevi et al.   SEMINARS IN CANCER BIOLOGY

Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies

(2019) Binbin Xie et al.   MOLECULAR CANCER THERAPEUTICS

Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: The Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting

(2018) Li Xu et al.   ACS Applied Materials & Interfaces

Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma

(2018) Hangxiang Wang et al.   Theranostics

Structure-Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy

(2018) Jianqin Wan et al.   ADVANCED FUNCTIONAL MATERIALS

Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro

(2017) Dmitriy Smolensky et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application

(2017) Philip Grossen et al.   JOURNAL OF CONTROLLED RELEASE

Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals

(2016) Barbara Lupo et al.   BMC BIOLOGY

Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies

(2016) Karel Ulbrich et al.   CHEMICAL REVIEWS

Polyethylenimine-functionalized silver nanoparticle-based co-delivery of paclitaxel to induce HepG2 cell apoptosis

(2016) Yinghua Li et al.   International Journal of Nanomedicine

Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications

(2016) Silvia Juliana Serrano-Gomez et al.   Molecular Cancer

Cabazitaxel-induced autophagy via the PI3K/Akt/mTOR pathway contributes to A549 cell death

(2016) Ruichao Huo et al.   Molecular Medicine Reports

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules

(2015) Yu Yu et al.   CANCER CELL

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer

(2014) Ekta Agarwal et al.   BMC CANCER

Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation

(2014) M Cioce et al.   Cell Death & Disease

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

(2013) P. Vrignaud et al.   CLINICAL CANCER RESEARCH

Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer

(2013) John M. Fitzpatrick et al.   EUROPEAN UROLOGY

Nanoparticle mediated non-covalent drug delivery

(2012) Tennyson Doane et al.   ADVANCED DRUG DELIVERY REVIEWS

Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma

(2012) Z. Li et al.   CLINICAL CANCER RESEARCH

Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: More than just AKT inhibition

(2011) Hui Sun et al.   CANCER LETTERS

Cabazitaxel in prostate cancer: stretching a string

(2010) Tanya B Dorff et al.   LANCET

LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling

(2010) L Li et al.   ONCOGENE

ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells

(2010) K. Zaoui et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein

(2009) M R Abedini et al.   ONCOGENE